Featuring an interview with Dr Bijal Shah. Published March 2026.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 1.25 credits
MOC types
ABIM — Medical KnowledgeUp to 1.25 points
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Pricing
100% of listed courses are free
240 of 240 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1.25 credits
- MOC · Up to 1.25 points
-
ReleasedMar 13, 2026
-
Last day to claim creditMar 15, 2027 5 months left
-
Research to Practice Oncology Today with Dr Neil Love: Role of CD19 x CD3 Bispecific T-Cell Engaging Antibodies in the Treatment of Acute Lymphoblastic Leukemia | 2026 (Audio Interview)
-
Research to Practice Oncology Today with Dr Neil Love: Empowering Community-Based Clinicians to Employ CD20 x CD3 Bispecific Antibodies in the Treatment of DLBCL | 2026 (Interview)
-
Research to Practice Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma What Happened at ASH 2025? | 2026 (Webinar Video Proceedings)
-
Answers in CME Inc. (AiCME) Evolving Care in B-ALL: From Questions to Answers on The Role of CD19 Bispecific T-Cell Engagers
-
Plexus Communications +1 Contemporary B-ALL Care: Practical Integration and Use of CD19-Directed Bispecific Antibodies
-
PVI, PeerView Institute for Medical Education Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice
